FDA delays approval of Alzheimer’s drug donanemab: What experts think

  • Eli Lilly & Company, the maker of anti-amyloid Alzheimer’s treatments, was expecting its experimental drug donanemab to be approved by the FDA this month.
  • However, the FDA has said it will hold a panel with external advisors to evaluate the safety and efficacy of donanemab before it makes a decision later this year.
  • Although the FDA’s decision was a surprise, some experts say a more cautious approach would be beneficial for patients, considering the drug is in early trials and there is little evidence of its benefits.

By Finn Cohen on March 13, 2024 — Fact checked by Jill Seladi-Schulman, Ph.D.

read full article

Call us at (888)-243-6602 to discuss how we can help keep your loved one safe and happy at home.